Tax unleashed: Fulminant Tax-positive Adult T-cell Leukemia/Lymphoma after failed allogeneic stem cell transplantation

Gourichon, David; Renand, Amédée; Lepelletier, Yves; Sibon, David; Suarez, Félipe; Rubio, Marie‐Thérèse; Buzyn, Agnès; Beljord, Kheira; Tanaka, Yuetsu; Varet, Bruno; Hermine, Olivier

doi:10.1016/j.jcv.2009.07.020

Cited by 1 publication

(2 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…HSCT has been proposed and currently performed as possible curative approach to another retrovirus, HTLV-1, etiologic agent of adult T-cell leukemia/lymphoma (ATLL) ( 222 ). According to non-recent data, the retrovirus HTLV-1 infects about twenty million people worldwide, mostly in East Asia ( 223 ), with <5% of them eventually developing ATLL ( 224 ). The viral trans-activator TAX plays a central role in the virus-related oncogenesis by exerting multiple deregulatory activities on key genes involved in T-cell homeostasis ( 222 ).…”

Section: Hsct As Immunotherapy In Viral Infectionsmentioning

confidence: 99%

“…Conversely, donor derived immune system after HSCT does express bZIP specific CD4+ T-cells, thus bearing the potential of targeting virus infected cells ( 225 ). The matter concerning TAX is more trivial, since TAX is not always expressed in ATLL cells, and sometimes the appearance of TAX expression seems to herald some kind of immune escape and an overwhelming relapse ( 224 ). Conversely, donor derived TAX-specific viral specific T-cells are found in the setting of HSCT ( 226 ), and have proved to be effective and long lasting in inhibiting HTLV-1 infected cells both in-vivo and in vitro ( 227 ).…”

Section: Hsct As Immunotherapy In Viral Infectionsmentioning

confidence: 99%

See 1 more Smart Citation

Viral Infections in HSCT: Detection, Monitoring, Clinical Management, and Immunologic Implications

et al. 2021

View full text Add to dashboard Cite

In spite of an increasing array of investigations, the relationships between viral infections and allogeneic hematopoietic stem cell transplantation (HSCT) are still controversial, and almost exclusively regard DNA viruses. Viral infections per se account for a considerable risk of morbidity and mortality among HSCT recipients, and available antiviral agents have proven to be of limited effectiveness. Therefore, an optimal management of viral infection represents a key point in HSCT strategies. On the other hand, viruses bear the potential of shaping immunologic recovery after HSCT, possibly interfering with control of the underlying disease and graft-versus-host disease (GvHD), and eventually with HSCT outcome. Moreover, preliminary data are available about the possible role of some virome components as markers of immunologic recovery after HSCT. Lastly, HSCT may exert an immunotherapeutic effect against some viral infections, notably HIV and HTLV-1, and has been considered as an eradicating approach in these indications.

show abstract